NCT03502681 2022-07-01
A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Big Ten Cancer Research Consortium
Phase 1 Terminated
Clinical Trials
4 trialsNCT01126749 2022-02-28
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Eisai Inc.
Phase 1/2 Terminated
NCT00278993 2014-07-14
Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy
Eisai Inc.
Phase 2 Completed
NCT00337077 2014-06-23
Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed